Phillipe Lutz joins Telormedix

pharmafile | May 13, 2010 | Appointment | Research and Development |  appointment, research and development, telormedix 

Swiss clinical stage biopharmaceutical company Telormedix has appointed Phillipe Lutz chief financial officer.

He joins the company from Synosia Therapeutics, where he chief financial officer for the last two years.

While at Synosia Therapeutics, he helped the company close a CHF32 million Series B financing round, which was ranked as the largest private Swiss biotech financing in 2008.

Prior to Synosia, he worked for nine years at Credit Suisse in Zurich contributing to a broad range of equity market transactions, including a number of IPOs, and rising to VP of the global markets solutions group.

“Philippe brings with him considerable knowledge and strength in the areas of financial and commercial development, a crucial addition to the leadership team as Telormedix steps up to the demands of clinical programmes,” said Dr Johanna Holldack, chief executive of Telormedix.